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Celecoxib as an Adjuvant to Fluvoxamine in Moderate 
to Severe Obsessive-compulsive Disorder: A Double-
blind, Placebo-controlled, Randomized Trial
Obsessive-compulsive behavior is also the main 
characteristic feature of pediatric autoimmune 
neuropsychiatric disorders associated with strep-
tococcal infection (PANDAS) syndrome. Etio-
pathogenesis and symptom exacerbation of 
PANDAS have been attributed to an inappropri-
ate immune response to streptococcal infection 
resulting in its central nervous system manifes-
tations, which include OCD and tics [9]. Interest-
ingly, while immunomodulatory therapeutic 
modalities including plasma exchange and intra-
venous immunoglobulin therapy have shown 
somewhat promising results in improving neu-
ropsychiatric symptoms of PANDAS [10], there is 
no conclusive evidence for the probable benefi-
cial role of antibiotics in reducing PANDAS symp-
toms [11] that would further indicate the role of 
autoimmunity in the etiopathogenesis of PAN-
DAS. The role of autoimmune responses in the 
etiopathogenesis of OCD may also be supported 
by a decrease in the number of regulatory T cells 
as well as mild dysregulation of other inflamma-
tory cell types in blood samples of OCD patients 
compared to age- and sex-matched healthy con-
trols [12].
Introduction
▼
Obsessive-compulsive disorder (OCD) is a rela-
tively common psychological disorder with a 
reported lifetime prevalence of 1–3 % in the gen-
eral population [1]. Currently, selective serotonin 
reuptake inhibitors (SRIs) and/or cognitive-
behavioral therapy, particularly exposure and 
response prevention (ERP), are first-line medica-
tions of choice in patients with mild to moderate 
OCD [2, 3]. Unfortunately, SRIs usually reduce the 
severity of OCD symptoms by as little as 20–30 % 
[4] and only 40–60 % of OCD patients achieve sat-
isfactory results [5–7]. Hence, an increasing 
number of studies have focused on the develop-
ment of augmentative agents in the management 
of OCD [1]. There is a growing body of evidence 
indicating the probable role of inflammatory 
processes and immune dysregulation in the eti-
opathogenesis of OCD. OCD has been reported to 
be associated with autoimmune disorders trig-
gered by inflammatory processes such as strepto-
coccal infections [8].
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Abstract
▼
Introduction: A growing body of evidence 
implicates inflammatory cascades in the patho-
physiology of obsessive-compulsive disorder 
(OCD), making this pathway a target for devel-
opment of novel treatments.
Methods: 50 outpatients with moderate 
to severe OCD participated in the trial, and 
underwent 10 weeks of treatment with either 
celecoxib (200 mg twice daily) or placebo as 
an adjuvant to fluvoxamine. Participants were 
investigated using Yale-Brown Obsessive Com-
pulsive Scale (Y-BOCS). The main outcome meas-
ure was to assess the efficacy of celecoxib in 
improving the OCD symptoms.
Results: General linear model repeated meas-
ures demonstrated significant effect for time × 
 treatment interaction on the Y-BOCS total scores 
[F (1.38, 66.34) = 6.91, p = 0.005]. Kaplan-Meier 
estimation with log-rank test demonstrated sig-
nificantly more rapid response in the celecoxib 
group than the placebo group (p < 0.001). There 
was no significant difference in adverse event 
frequencies between the groups.
Discussion: The results of the current study 
suggest that celecoxib could be a tolerable and 
effective adjunctive treatment for more rapid 
and more satisfying improvements in OCD symp-
toms.
 *  The first two authors contributed equally to this work
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Along with OCD, the findings of numerous studies also suggested 
the role of proinflammatory cytokines in the etiopathogenesis of 
several neuropsychiatric disorders including schizophrenia, bipo-
lar disorder and major depressive disorder [13]. Furthermore, 
investigation of the therapeutic opportunities provided by this 
thesis has resulted in several studies on the treatment of neu-
ropsychiatric disorders with promising results [14, 15].
Celecoxib is a non-steroidal anti-inflammatory drug (NSAID) 
and selective inhibitor of cyclooxygenase-2 (COX-2), a known 
promoter of both inflammation and pain. COX-2 inhibitors have 
been proven to be beneficial in prevention of glutamate-medi-
ated neuronal death and suppression of proinflammatory 
cytokines [16, 17]. Celecoxib also has the advantage of reduced 
gastrointestinal complications compared to other NSAIDs.
Based on the currently available data, we hypothesized that the 
anti-inflammatory effects of celecoxib may be beneficial in the 
medication management of OCD. The present 10-week, double-
blind, placebo-controlled trial aimed to evaluate the safety and 
efficacy of adjunctive therapy with celecoxib in improving the 
clinical symptoms of moderate to severe OCD.
Patients and Methods
▼
Trial design and setting
A single-center, 10-week, randomized, double-blind, placebo-
controlled, parallel-group trial was conducted in the outpatient 
clinics of Roozbeh Psychiatric Hospital (Tehran University of 
Medical Sciences, Tehran, Iran) from January 2014 to November 
2014. Approval was obtained from the Institutional Review 
Board (IRB) of Tehran University of Medical Science (Grant No: 
23218). The trial was performed according to the Declaration of 
Helsinki and its subsequent revisions. All patients signed an 
informed consent prior to study entry. The trial was registered at 
the Iranian registry of clinical trials (www.irct.ir; registration 
number: IRCT201312181556N56).
Participants
Men and women, aged between 18–60 years, with a diagnosis of 
OCD according to the Diagnostic and Statistical Manual of Men-
tal Disorders, Fourth Edition, Text Revision (DSM-IV-TR) and a 
Yale-Brown Obsessive Compulsive Scale (Y-BOCS) score of  ≥ 21 
to have moderate to severe OCD, were eligible to take part in the 
study. Exclusion criteria were as follows: any other mental disor-
der on DSM-IV axis I, alcohol or substance (with the exception of 
nicotine) dependence, intelligence quotient < 70, any serious 
medical illness including cardiac, hepatic and renal disease, 
ingestion of any psychotropic medications during the last 6 
weeks, pregnancy, breast feeding and rises in liver transaminase 
to 3 times the upper limit of normal or higher.
Interventions
Eligible participants were randomly assigned to receive either 
200 mg celecoxib (celebrex, Pfizer, 200 mg capsule) twice daily 
or placebo in the same manner for 10 weeks. All patients, regard-
less of their treatment group, also received fluvoxamine 100 mg/
day for the first 4 weeks of the study followed by 200 mg/day for 
the rest of the trial course.
Outcomes
All patients were assessed using Y-BOCS at baseline and weeks 4 
and 10. A psychiatrist with good experience in implementing 
the Y-BOCS who had been involved in several clinical trials was 
in charge of rating the patients. The main outcome measure of 
this trial was evaluation of celecoxib efficacy in improvement of 
Y-BOCS total score compared to placebo using the general linear 
repeated measure model. Partial response and complete 
response were defined as 25 % and 35 % reduction in the Y-BOCS 
score, respectively. A Y-BOCS score < 16 was considered as remis-
sion. Adverse events were systematically evaluated at each time 
point.
Sample size
Assuming a difference of 4 on the Y-BOCS total score between 
the celecoxib group and the placebo group with a standard devi-
ation (SD) of 4.5, a power of 80 %, and a two-sided significance 
level of 5 %, a sample size of 42 was needed. Considering a 20 % 
attrition rate, a final sample size of 54 was planned.
Randomization, allocation, concealment and blinding
Generation of randomization codes was performed by a com-
puterized random number generator (blocks of 4, allocation 
ratio 1:1). Concealment of allocation was performed using 
sequentially numbered and sealed packages. Separate people 
were responsible for random allocation and rating of the 
patients. The patients, research investigators, rater and the stat-
istician were all blinded to the allocated treatment. Celecoxib 
and placebo capsules were completely identical in their shape, 
color, size, texture, and odor. The placebo rate anticipation was 
also assessed by the participants, and the rater at the study end.
Statistical analysis
All analyses were carried out according to the intention-to-treat 
principles with at least one post-baseline measurement. Con-
tinuous variables were reported as mean ± standard deviation 
(SD) and categorical variables were reported as frequency (per-
centage). Baseline continuous variables were compared using an 
independent t-test. A general linear model repeated measure 
was used to evaluate time × treatment interaction considering 
the treatment group (celecoxib vs. placebo) as the between-sub-
ject factor and the study measurements as the within-subject 
factor (time). Greenhouse-Geisser adjustment in degrees of 
freedom was made if Mauchly’s test of sphericity was signifi-
cant. An independent t-test and Cohen’s d effect size were used 
to compare score change from baseline to each time interval 
between the 2 study groups. Categorical variables were com-
pared using chi-square test or Fisher’s exact test as appropriate. 
The time needed to respond to treatment was compared 
between the celecoxib and the placebo groups using Kaplan-
Meier estimation with log-rank test. Statistical Package of Social 
Science Software (SPSS version 20, IBM Company, Armonk NY, 
USA) was used for statistical analysis and the graphs were drawn 
using SigmaPlot (version 12).
Results
▼
Participants and baseline characteristics
A total of 104 participants screened for eligibility criteria, among 
them 54 patients, were randomly assigned to receive either 
celecoxib plus fluvoxamine (n = 27) or placebo plus fluvoxamine 
(n = 25). 50 patients (25 in each group) had at least one post-
baseline measurement and a similar number of study partici-
pants completed the trial ( ●▶	 Fig. 1). Baseline characteristics of 
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the patients were not significantly different between the groups 
( ●▶	 Table 1).
Outcome
Y-BOCS total score
General linear model repeated measures demonstrated signifi-
cant effect for time × treatment interaction on Y-BOCS total score 
during the trial course [F (1.38, 66.34) = 6.91, p = 0.005] ( ●▶	 Fig. 2a). 
At the study conclusion, remission achieved in 15 (60 %) patients 
in the celecoxib group was compared with 8 (32 %) patients in 
the placebo group (p < 0.047). Significantly, higher partial and 
complete response rates were also observed in the celecoxib 
group than the placebo group at the end of the trial ( ●▶	 Table 2). 
An independent t-test demonstrated significantly greater reduc-
tion in Y-BOCS total score in the celecoxib group than the placebo 
group at weeks 4 and 10 ( ●▶	 Table 3). Kaplan-Meier estimation 
showed that a shorter time was needed in the celecoxib group 
than the placebo group for partial response, p < 0.001.
Y-BOCS obsession subscale score
General linear model repeated measures demonstrated signifi-
cant effect for time × treatment interaction on Y-BOCS total score 
during the trial course [F (1.44, 69.33) = 7.17, p = 0.004] ( ●▶	 Fig. 2b). 
An independent t-test demonstrated significantly greater reduc-
tion in Y-BOCS obsession subscale scores in the celecoxib group 
than the placebo group at weeks 4 and 10 ( ●▶	 Table 3).
Y-BOCS compulsion subscale score
General linear model repeated measures demonstrated signifi-
cant effect for time × treatment interaction on Y-BOCS total score 
during the trial course [F (1.35, 64.90) = 3.99, p = 0.038] ( ●▶	 Fig. 
2c). Independent t-test demonstrated significantly greater 
reduction in Y-BOCS obsession subscale scores in the celecoxib 
group than the placebo group at weeks 10 ( ●▶	 Table 3).
Adverse events
Frequency of adverse events did not differ significantly between 
treatment groups ( ●▶	 Table 4). No serious adverse events or 
deaths occurred.
Blinding
The participants and the rater were unsure about the treatment 
allocation in more than 50 % of the allocations.
Discussion
▼
The results of the current study showed that the administration 
of celecoxib, as an adjuvant agent in addition to fluvoxamine, is 
significantly superior to fluvoxamine monotherapy in reducing 
both obsessive and compulsive symptoms and achieving a more 
rapid response to treatment in patients with moderate to severe 
OCD. The use of celecoxib also appeared to be safe and well tol-
erated in our study population and no clinically significant 
adverse effect was reported. The response to treatment in the 
placebo arm who received monotherapy with fluvoxamine was 
similar to the previous reports of treatment outcome with SRIs 
in OCD patients [4]. Fluvoxamine monotherapy resulted in about 
30 % reduction in OCD symptoms (9.4 points on Y-BOCS total 
score). Celecoxib plus fluvoxamine resulted in about 50 % reduc-
Variable Celecoxib group (n = 25) Placebo group (n = 25) P-value
age, years, mean ± SD 33.28 ± 8.64 31.16 ± 8.90 0.40
weight (kg) 79.3 ± 11.2 78.1 ± 11.4 0.70
height (cm) 171.6 ± 14.3 172.8 ± 12.2 0.71
sex, female, n ( %) 9 (36 %) 10 (40 %) 0.77
duration of the disease (years), mean ± SD 5.12 ± 2.87 6.40 ± 3.74 0.18
single: married 8 (32 %): 17 (68 %) 10 (40 %): 15 (60 %) 0.77
education 0.13
 – primary or secondary school 8 (32 %) 5 (20 %)
 – diploma 13 (52 %) 9 (36 %)
 – university degree 4 (16 %) 11 (44 %)
Y-BOCS total score, mean ± SD 30.24 ± 3.87 29.48 ± 1.69 0.37
Y-BOCS obsession subscale, mean ± SD 16.20 ± 2.14 15.36 ± 1.35 0.10
Y-BOCS compulsion subscale, mean ± SD 14.04 ± 2.59 14.12 ± 1.01 0.89
baseline HDRS score, mean ± SD 7.24 ± 1.12 6.98 ± 1.48 0.48
medications history Fluoxetine: 15;  
Clomipramine: 10;  
Fluvoxamine: 8
Fluoxetine: 16;  
Clomipramine: 12;  
Fluvoxamine: 10
n, number; SD, standard deviation; Y-BOCS: Yale-Brown Obsessive Compulsive Scale; HDRS, Hamilton depression rating scale
Table 1 Baseline characteristics 
according to the treatment group.
Fig. 1 Flow diagram of the trial.
104 patients screened
54 randomized
27 assigned to fluvoxamine+celecoxib
25 completed trial 25 completed trial
Discontinued:
1 withdrawn consent at
week 1
1 excluded due to substance
dependence at week 1
Discontinued:
2 withdrawn consent at
week 1
27 assigned to fluvoxamine+placebo
50 excluded:
34 did not meet inclusion criteria
16 met exclusion criteria
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tion in OCD symptoms (14.7 points on Y-BOCS total score) by the 
trial conclusion. Since baseline characteristics of patients in the 
2 study groups did not differ significantly, it cannot explain the 
differences observed in the efficacy of fluvoxamine and placebo 
as adjuvant agents.
The findings of the present study are consistent with the report 
of Sayyah et al. on augmentative treatment with celecoxib in 
patients with OCD. They investigated the efficacy of the same 
celecoxib dosage as an adjuvant therapy to fluoxetine in the 
management of OCD in an 8-week clinical trial [18]. They found 
that those in the celecoxib group showed a greater improvement 
of OCD symptoms compared to controls who received fluoxetine 
and placebo. The superior effect of celecoxib compared to pla-
cebo was observed as soon as 2 weeks after the initiation of 
therapy and was still significant at the study end at week 8. In 
agreement with their report, we found a significantly greater 
improvement of OCD symptoms in the first assessment after 
receiving medication for 4 weeks and the results were repeated 
at week 10. The beneficial effects of celecoxib in rapid reduction 
of obsessive and compulsive symptoms may be explained mainly 
by the role of COX-2 inhibitors in the suppression of inflamma-
Table 4	 The	frequency	of	different	types	of	adverse	events	in	the	study	
population.
Adverse event Celecoxib 
group (n = 25)
Placebo  
group (n = 25)
P-value
increased appetite, n,  % 8 (32) 3 (12) 0.09
daytime drowsiness, n,  % 7 (28) 5 (20) 0.51
slowed movement, n,  % 7 (28) 2 (8) 0.065
morning drowsiness, n,  % 6 (24) 3 (12) 0.46
dizziness, n,  % 5 (20) 4 (16) 1.00
nervousness, n,  % 5 (20) 2 (8) 0.42
restlessness, n,  % 4 (16) 3 (12) 1.00
dry mouth, n,  % 4 (16) 5 (20) 1.00
fatigue, n,  % 3 (12) 3 (12) 1.00
diarrhea, n,  % 3 (12) 0 (0) 0.23
abdominal pain, n,  % 3 (12) 3 (9) 1.00
Yyawning, n,  % 3 (12) 5 (20) 0.70
headache, n,  % 3 (12) 4 (16) 1.00
twitches, n,  % 2 (8) 3 (12) 1.00
loss of appetite, n,  % 1 (4) 5 (20) 0.19
Y-BOCS score Celecoxib 
group (n = 25)
Placebo 
group (n = 25)
Mean	difference	celecoxib-
placebo (95 % CI)
Cohen’ 
d
P-value
total (week 4) 7.44 ± 4.04 4.76 ± 3.91 2.68 (0.42–4.94) 0.67 0.02
total (week 10) 14.68 ± 4.82 9.40 ± 7.80 5.28 (1.57–8.99) 0.81 0.006
obsession (week 4) 4.48 ± 2.61 2.56 ± 2.53 1.92 (0.46–3.38) 0.74 0.01
obsession (week 10) 8.56 ± 3.74 5.08 ± 4.50 3.48 (1.13–5.83) 0.84 0.005
compulsion (week 4) 2.96 ± 1.93 2.20 ± 1.87 0.76	(	−	0.32–1.84) 0.40 0.16
compulsion (week 10) 6.44 ± 2.08 4.32 ± 4.44 2.12 (0.13–4.11) 0.61 0.04
CI,	confidence	interval;	n	number;	Y-BOCS,	Yale-Brown	Obsessive	Compulsive	Scale
Table 2 Comparison of changes 
in the Yale-Brown Obsessive Com-
pulsive Scale total and subscales 
scores from baseline between 
the 2 groups using independent 
t-test.
Fig. 2	 Repeated-measure	analysis	of	variance	for	the	effect	of	2	treatments	on	the	Yale-Brown	Obsessive	Compulsive	Scale	(Y-BOCS)	total	a,  
obsession b and compulsion c	scores	(mean	±	SD;		*	P	<	0.05).	NS,	not	significant.
40
30
20
10
0
0 4 10 0 4 10
18
16
14
12
10
8
6
4 4
18
16
14
12
10
8
6
0 104
Y-
BO
CS
 to
ta
l s
co
re
Y-
BO
CS
 o
bs
es
si
on
 s
ub
sc
al
e 
sc
or
e
Y-
BO
CS
 c
om
pu
ls
io
n 
su
bs
ca
le
 s
co
re
Trial weeks Trial weeks Trial weeks
NS
NS
*
NS
NS *
NS
NS
*
Celecoxib group
Placebo group
a b c
Outcome Celecoxib 
group
Placebo 
group
P-value power Odds ratio (95 % CI)
number ( %) of PRs at week 4 9 (36 %) 4 (16 %) 0.10 0.25 2.95 (0.76–11.33)
number ( %) of PRs at week 10 23 (92 %) 10 (40 %) 0.0001 0.97 17.25 (3.31–89.97)
number ( %) of CRs at week 4 3 (12 %) 4 (16 %) 1.00 0.02 0.71 (0.14–3.58)
number ( %) of CRs at week 10 22 (88 %) 9 (36 %) 0.0001 0.97 13.03 (3.03–55.95)
number ( %) of remitters at week 4 2 (8 %) 1 (4 %) 1.00 0.02 2.08 (0.17–24.61)
number ( %) of remitters at week 10 15 (60 %) 8 (32 %) 0.047 0.39 3.18 (0.99–10.17)
CI,	confidence	interval;	PR,	partial	responders;	CR,	complete	responders
Table 3 Comparison of outcome 
indexes between the 2 groups.
D
ow
nl
oa
de
d 
by
: I
ra
n 
Un
ive
rs
ity
 o
f M
ed
ica
l S
cie
nc
es
. C
op
yr
ig
ht
ed
 m
at
er
ia
l.
140 Original Paper
Shalbafan M et al. Celecoxib in OCD … Pharmacopsychiatry 2015; 48: 136–140
tory processes in the brain. COX-2 plays an important role in the 
initiation of inflammatory processes by catalyzing the conver-
sion of arachidonic acid to prostaglandin H2 [19]. Prostaglandin 
H2 itself is a precursor for other biologically active molecules 
involved in further regulation of inflammatory cascades includ-
ing prostaglandin D2, prostaglandin E2, prostacyclin and throm-
boxane A2 [20]. Most recently, Konuk et al. evaluated the plasma 
levels of 2 proinflammatory cytokines, interleukin-6 (IL-6) and 
tumor necrosis factor(TNF)-α, among OCD patients with no 
major neuropsychological disorder who had not have received 
any psychotropic agents or NSAIDs for at least 3 months prior to 
blood sampling [21]. They reported higher plasma levels of both 
IL-6 and TNF-α in OCD patients compared to healthy controls. 
Moreover, they found a negative correlation between TNF-α 
level and the onset of disease as well as a weak correlation 
between IL-6 levels and duration of illness. The authors sug-
gested that new therapeutic modalities can be developed based 
on the speculated role of inflammation in the etiopathogenesis 
of OCD. Nevertheless, a recent meta-analysis showed that overall 
plasma levels of IL-1β are reduced in OCD patients relative to 
controls, while there is no overall difference in TNF-α and IL-6 
plasma levels [22]. Interestingly, celecoxib is known to signifi-
cantly reduce elevated levels of both IL-6 and TNF-α, which fur-
ther supports the importance of its anti-inflammatory 
characteristics in improving clinical symptoms of OCD patients 
[14, 15].
In the present study, celecoxib was administrated with a dosage 
of 200 mg twice daily with no serious adverse events. We have 
already reported the safety and tolerability of this practice in 
several previous studies [14, 15]. We did not witness any serious 
cardiovascular adverse effects here. Indeed, the lack of such 
findings can be attributed to the low doses of celecoxib adminis-
tered, short duration of therapy and follow-up, and relatively 
small number of patients investigated. Limitations of the pre-
sent study include: small sample size, short follow-up period 
and no assessment of proinflammatory cytokines.
In conclusion, the results of the current study suggest that the 
administration of celecoxib as an adjuvant agent with SRIs might 
help in achieving rapid and more satisfying improvements in 
OCD symptoms. Further randomized controlled trials with 
larger sample sizes, longer study duration, and proinflammatory 
cytokine assessment are warranted in order to confirm the ben-
eficial effects of celecoxib in long-term management of OCD.
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